The sulfotransferase 1A1 (SULT1A1) antibody is a crucial tool for studying the SULT1A1 enzyme, a member of the cytosolic sulfotransferase family. SULT1A1 catalyzes the sulfonation of a wide range of endogenous compounds (e.g., hormones, neurotransmitters) and xenobiotics (e.g., drugs, environmental toxins), facilitating their excretion or bioactivation. This phase II metabolism enzyme is highly expressed in the liver, intestines, and platelets, with genetic polymorphisms (e.g., *SULT1A1*2 and *SULT1A1*3 alleles) influencing its activity and disease susceptibility.
SULT1A1 antibodies are designed to detect and quantify the enzyme in research and diagnostic settings. Polyclonal and monoclonal variants target specific epitopes, enabling applications like Western blotting, immunohistochemistry (IHC), and ELISA. These antibodies help investigate SULT1A1's role in drug metabolism, cancer (e.g., altered expression in colorectal and breast cancers), and hormone regulation. Dysregulation of SULT1A1 has been linked to carcinogen activation, endocrine disorders, and variable drug responses, making its detection vital for personalized medicine and toxicology studies. Validation of antibody specificity ensures accurate profiling of tissue-specific expression and isoform differentiation within the SULT family.